Daniel Joseph Oconnell Sells 12,941 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell sold 12,941 shares of the business’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $1.76, for a total value of $22,776.16. Following the completion of the transaction, the chief executive officer owned 598,898 shares of the company’s stock, valued at $1,054,060.48. This trade represents a 2.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Daniel Joseph Oconnell also recently made the following trade(s):

• On Monday, January 12th, Daniel Joseph Oconnell sold 5,388 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.73, for a total value of $9,321.24.
• On Thursday, January 8th, Daniel Joseph Oconnell sold 8,143 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.82, for a total value of $14,820.26.
• On Wednesday, January 7th, Daniel Joseph Oconnell sold 37,755 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.99, for a total value of $75,132.45.
• On Tuesday, January 6th, Daniel Joseph Oconnell sold 5,102 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.97, for a total transaction of $10,050.94.
• On Monday, January 5th, Daniel Joseph Oconnell sold 4,649 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.97, for a total transaction of $9,158.53.

Acumen Pharmaceuticals Price Performance

Acumen Pharmaceuticals stock opened at $1.73 on Wednesday. Acumen Pharmaceuticals, Inc. has a 1 year low of $0.86 and a 1 year high of $2.46. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. The firm has a 50 day moving average price of $1.93 and a 200 day moving average price of $1.69. The company has a market cap of $104.79 million, a price-to-earnings ratio of -0.78 and a beta of 0.23.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.19. Sell-side analysts predict that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On Acumen Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. acquired a new stake in Acumen Pharmaceuticals in the third quarter valued at approximately $27,000. Marex Group plc purchased a new position in shares of Acumen Pharmaceuticals in the second quarter valued at $39,000. AQR Capital Management LLC acquired a new stake in Acumen Pharmaceuticals during the 1st quarter valued at $46,000. Qube Research & Technologies Ltd grew its holdings in Acumen Pharmaceuticals by 160.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company’s stock valued at $67,000 after purchasing an additional 35,424 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Acumen Pharmaceuticals during the 2nd quarter worth $160,000. 71.01% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Acumen Pharmaceuticals

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Analyst and institutional support — ABOS carries a consensus “Moderate Buy” from sell‑side analysts with a consensus price target near $6.75, and several institutions have recently built or increased stakes (Hudson Bay, SG Americas, Susquehanna, Bank of America). This underpins longer‑term demand and may limit downside. MarketBeat Coverage
• Neutral Sentiment: Short‑interest data is reported as effectively zero for Jan. 12, but the published figures contain inconsistencies (NaN); the short‑interest snapshot is unreliable and should not be relied on for explaining intraday moves. Monitor future updates for clarity.
• Neutral Sentiment: Insiders retain large holdings — despite recent sales, CEO Daniel O’Connell still owns ~593k shares, CFO Matt Zuga ~210k and COO Russell Barton ~123k. Large remaining insider stakes can be seen as alignment with shareholders even after sales.
• Negative Sentiment: Clustered insider selling — multiple senior executives sold shares between Jan. 5–12. CEO Daniel O’Connell sold ~26,472 shares across three trades (avg prices roughly $1.73–$1.82), CFO Matt Zuga sold 6,888 shares at $1.82 (and additional small sales earlier in the week), and COO Russell Barton sold 3,530 shares at $1.86. The concentration of sales (roughly ~37k shares total) is likely weighing on near‑term sentiment. SEC filings and press coverage: SEC Form 4 AmericanBankingNews: CEO sale
• Negative Sentiment: CFO’s repeated small sales — Matt Zuga executed multiple sales in early January (Jan. 5–8) at prices between ~$1.96–$1.82, totaling roughly $40k–$45k across those trades; repeated disposals can be interpreted negatively by active traders. Coverage: InsiderTrades alert

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Bank of America reduced their price objective on Acumen Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Friday. Finally, Wall Street Zen upgraded shares of Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.75.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.